Category - Developments

Developments

FDA clears Ziopharm Oncology IND for T-cell receptor therapy

The FDA has cleared Ziopharm Oncology’s (NASDAQ:ZIOP) IND for its T-cell receptor therapy (TCR-T) for the treatment of solid tumors. Ziopharm’s TCR-T consists of T-cells that have been genetically modified to express...

June 11, 2019

Developments

Helius Medical PoNS study on brain activity in peer-reviewed journal

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) reported that a scientific paper entitled, “Human Translingual Neurostimulation Alters Resting Brain Activity in High-density EEG,” was published in the latest edition...

June 11, 2019

Developments

IntelGenx to add Ottawa site to Montelukast VersaFilm Phase 2a trial; first patient in study completes treatment

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced plans to add a new Ottawa site to its Montelukast VersaFilm Phase 2a clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD).

June 10, 2019

Developments

vTv Therapeutics reports positive topline results from Phase 2 diabetes trial

vTv Therapeutics (NASDAQ:VTVT) reported positive topline results from its Phase 2 trial of TTP399 in Type 1 diabetes (T1D) patients.

June 6, 2019

Developments

La Jolla Pharma reports interim results from Phase 2 hemochromatosis trial

La Jolla Pharmaceutical (NASDAQ:LJPC) reported results from a pre-specified interim analysis of its Phase 2 study of LJPC-401 in patients with hereditary hemochromatosis (HH).

June 6, 2019

Developments

Anavex doses first patient in Phase 2 Rett Syndrome trial

Anavex Life Sciences (NASDAQ:AVXL) dosed the first patient in its Phase 2 trial of ANAVEX2-73 for the treatment of Rett syndrome.

June 6, 2019

Developments

Axovant reports six-month data from Phase 2 Parkinson’s disease trial

Axovant Gene Therapies (NASDAQ:AXGT) reported six-month data from its Phase 2 trial of AXO-Lenti-PD, a gene therapy for Parkinson’s disease (PD). AXO-Lenti-PD uses a single lentiviral vector to deliver three genes...

June 6, 2019

Developments

ContraVir Pharma sets stage for CRV431 development in NASH with positive results in second model of liver fibrosis

ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that CRV431 significantly decreased the extent of fibrosis, or scarring of the liver, in a second animal model of liver fibrosis. CRV431 is a clinical stage cyclophilin...

June 6, 2019

Developments

FDA grants Sierra Oncology fast track designation for momelotinib

Sierra Oncology (NASDAQ:SRRA) received FDA fast track designation for momelotinib for the treatment of myelofibrosis. Momelotinib is designed to improve anemia that frequently occurs in myelofibrosis, or cancer of the...

June 5, 2019

Developments

AnaptysBio presents updated Phase 2a data of etokimab in asthma

AnaptysBio (NASDAQ:ANAB) presented updated Phase 2a data of etokimab for the treatment of severe eosinophilic asthma at the European Academy of Allergy and Clinical Immunology congress. Etokimab is a humanized anti...

June 5, 2019

Category - Developments

Subscribe